Oct 25, 2007

Vermillion Inc, Fremont, Calif, today announced that the company and its collaborators will present multiple studies on Vermillion’s ovarian cancer diagnostics program at the 15th International Meeting of the European Society of Gynecological Oncology (ESGO) in Berlin, Oct 28 to Nov 1. Data will showcase the company’s ovarian cancer triage test, which is designed to distinguish between benign and malignant pelvic masses. Presentations will also be made on the use of protein biomarkers to predict survival in patients with ovarian cancer and as potential tools to improve diagnosis of early-stage disease.

"The presentations at ESGO highlight the significant body of data validating the use of the biomarkers in our ovarian cancer diagnostics program," said Eric T. Fung, MD, PhD, Chief Scientific Officer, Vermillion Inc. "With enrollment completed for our ovarian cancer triage test trial, we are now conducting the data analysis and look forward to reporting top-line data results in December and preparing a submission to the US Food and Drug Administration for in vitro diagnostic clearance."